We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+9.87%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$469K
Cap. Flow
-$27M
Cap. Flow %
-9.03%
Top 10 Hldgs %
39.8%
Holding
92
New
15
Increased
30
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$9.95M
2
EHC icon
Encompass Health
EHC
+$8.69M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.99M
4
BIIB icon
Biogen
BIIB
+$5.15M
5
PFE icon
Pfizer
PFE
+$4.29M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$10.6M
2
GMED icon
Globus Medical
GMED
+$10.3M
3
MRK icon
Merck
MRK
+$10.2M
4
BDX icon
Becton Dickinson
BDX
+$8.54M
5
STJ
St Jude Medical
STJ
+$7.48M

Sector Composition

Rank Sector Weight
1 Healthcare 89.39%
2 Financials 3.11%
3 Technology 0.63%
4 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$162B
$4.29M 1.43%
42,410
+11,410
+37% +$1.19M
WBA
27
DELISTED
Walgreens Boots Alliance
WBA
$4.21M 1.41%
+49,414
New +$4.2M
PFE icon
28
Pfizer
PFE
$143B
$4.17M 1.4%
+136,282
New +$4.29M
TNDM icon
29
Tandem Diabetes Care
TNDM
$1.34B
$3.79M 1.27%
32,057
+11,048
+53% +$1.1M
BKD icon
30
Brookdale Senior Living
BKD
$3.49B
$3.73M 1.25%
201,820
+167,320
+485% +$3.6M
LH icon
31
Labcorp
LH
$25B
$3.69M 1.23%
34,701
-4,866
-12% -$502K
AMAG
32
DELISTED
AMAG Pharmaceuticals
AMAG
$3.36M 1.12%
111,180
+17,080
+18% +$552K
UHS icon
33
Universal Health Services
UHS
$10.2B
$3.24M 1.08%
27,107
-30,368
-53% -$3.71M
CELG
34
DELISTED
Celgene Corp
CELG
$3.19M 1.07%
26,680
+5,580
+26% +$646K
CI icon
35
Cigna
CI
$73.7B
$3.13M 1.05%
21,420
-3,880
-15% -$533K
SHPG
36
DELISTED
Shire pic
SHPG
$3.04M 1.02%
14,810
+5,910
+66% +$1.23M
A icon
37
Agilent Technologies
A
$39.1B
$2.91M 0.97%
69,685
+43,620
+167% +$1.69M
HRC
38
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$2.91M 0.97%
+60,524
New +$3.09M
HOLX
39
DELISTED
Hologic
HOLX
$2.53M 0.85%
65,500
+57,100
+680% +$2.22M
MRK icon
40
Merck
MRK
$322B
$2.46M 0.82%
48,737
-203,207
-81% -$10.2M
CVS icon
41
CVS Health
CVS
$133B
$2.43M 0.81%
+24,900
New +$2.44M
VRTX icon
42
Vertex Pharmaceuticals
VRTX
$121B
$2.3M 0.77%
18,250
-8,450
-32% -$1.02M
ALR
43
DELISTED
AlerisLife Inc
ALR
$2.25M 0.75%
70,789
-90,013
-56% -$3.03M
ZVRA icon
44
Zevra Therapeutics
ZVRA
$562M
$2.08M 0.7%
6,555
+2,634
+67% +$715K
WMGI
45
DELISTED
Wright Medical Group Inc
WMGI
$1.9M 0.64%
+78,628
New +$1.7M
CSLT
46
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.89M 0.63%
442,508
-275,700
-38% -$1.18M
GI
47
DELISTED
EndoChoice Holdings, Inc.
GI
$1.87M 0.63%
223,963
+4,277
+2% +$41.1K
AMPH icon
48
Amphastar Pharmaceuticals
AMPH
$879M
$1.82M 0.61%
127,950
+4,691
+4% +$62K
PARN
49
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.69M 0.57%
435,627
+1,761
+0.4% +$6.7K
ZLTQ
50
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$1.66M 0.55%
+58,100
New +$1.83M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Endurant Capital Management held 92 positions worth $299M, down 0.16% from $300M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management withdrew a net $27M in Q4 2015, closing 15 positions and reducing 32 holdings. Its most notable exit was CR Bard Inc., an estimated $3.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Endurant Capital Management opened a new position in Pfizer worth $4.17M.

  • Endurant Capital Management's largest Q4 2015 buy was Pfizer: 136,282 shares worth $4.17M.
  • Endurant Capital Management added most to Zimmer Biomet in Q4 2015, an estimated $9.95M increase.
  • Endurant Capital Management's biggest Q4 2015 reduction was Thermo Fisher Scientific, cutting an estimated $10.6M.
  • Endurant Capital Management fully exited CR Bard Inc. in Q4 2015, selling an estimated $3.71M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $299M portfolio in Q4 2015.
  • Endurant Capital Management opened 15 new positions and closed 15 in Q4 2015.
  • Endurant Capital Management's portfolio value fell 0.16% quarter-over-quarter to $299M.

Based on Endurant Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.